- Home
- MFIN vs SIGA Comparison
MFIN vs SIGA Comparison
Compare MFIN & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | SIGA |
|---|---|---|
| Founded | 1995 | 1995 |
| Country | United States | United States |
| Employees | 179 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.0M | 223.8M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | MFIN | SIGA |
|---|---|---|
| Price | $11.92 | $3.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 75.4K | ★ 607.7K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | 5.18% | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.02 | $224.81 |
| P/E Ratio | ★ $6.21 | $23.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $2.83 |
| 52 Week High | $12.07 | $9.45 |
Technical Indicators
Market Signals| Indicator | MFIN | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 69.51 | 44.02 |
| Support Level | $9.19 | $3.01 |
| Resistance Level | N/A | $4.84 |
| Average True Range (ATR) | 0.29 | 0.13 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 86.35 | 68.97 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.